Adc Therapeutics Sa (ADCT)

$3.71 +0.01 (0.27%)
Market Cap 473.21M
Revenue (ttm) 70.84M
Net Income (ttm) -157.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -222.83%
Debt to Equity Ratio -0.48
Volume 553,592
Avg Vol 1,240,890
Day's Range N/A - N/A
Shares Out 123.88M
Stochastic %K 63%
Beta 1.95
Analysts Strong Sell
Price Target $8.00

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 653 02 00
Address:
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland
Rox22
Rox22 Jan. 11 at 11:16 PM
$ADCT ruff!
0 · Reply
Spartrap
Spartrap Jan. 9 at 5:00 PM
$ADCT lol $73M what a dog 😂
1 · Reply
JohnTrack
JohnTrack Jan. 9 at 1:59 AM
$ADCT preliminary results https://www.rapidticker.com/news/adct-adc-therapeutics-provides-preliminary-fourth-e37d3d
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 8 at 9:32 PM
$ADCT
0 · Reply
JohnTrack
JohnTrack Jan. 2 at 11:21 PM
$ADCT watching for higher lows...
0 · Reply
JohnTrack
JohnTrack Jan. 2 at 9:34 PM
$ADCT quick blurb hit the feed!! https://www.rapidticker.com/news/adct-adc-therapeutics-announces-new-employee-9825ed
0 · Reply
fmalad
fmalad Dec. 30 at 2:22 AM
$ADCT it’s in an uptrend. Stop looking at a 5 day chart and stop day trading!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 10:15 PM
$ADCT RSI: 56.19, MACD: -0.1343 Vol: 0.37, MA20: 3.80, MA50: 4.02 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SamHot
SamHot Dec. 23 at 9:59 PM
$ADCT I couldn't resist
1 · Reply
Justrise07
Justrise07 Dec. 11 at 6:08 PM
$ADCT silent monster ! Shorts already started recovering! They read the new update & did dd , unstoppable next stop , welcome $CAPR
0 · Reply
Latest News on ADCT
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

Jan 8, 2026, 4:05 PM EST - 6 days ago

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:15 AM EST - 6 days ago

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ADC Therapeutics Announces New Employee Inducement Grant

Jan 2, 2026, 4:05 PM EST - 12 days ago

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript

Dec 3, 2025, 10:53 AM EST - 6 weeks ago

ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 3, 2025, 7:30 AM EST - 6 weeks ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Dec 2, 2025, 4:05 PM EST - 6 weeks ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Dec 1, 2025, 4:05 PM EST - 6 weeks ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 11:21 AM EST - 2 months ago

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 10, 2025, 7:30 AM EST - 2 months ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Nov 3, 2025, 7:15 AM EST - 2 months ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

ADC Therapeutics to Present at November Investor Conferences

Oct 27, 2025, 7:15 AM EDT - 2 months ago

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics Announces $60 Million Private Placement

Oct 13, 2025, 7:30 AM EDT - 3 months ago

ADC Therapeutics Announces $60 Million Private Placement

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:15 AM EDT - 5 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 11:27 AM EDT - 5 months ago

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 12, 2025, 7:30 AM EDT - 5 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Aug 5, 2025, 4:05 PM EDT - 5 months ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:05 PM EDT - 7 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 16, 2025, 7:15 AM EDT - 7 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:45 AM EDT - 7 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

Jun 12, 2025, 6:30 AM EDT - 7 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:36 PM EDT - 8 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 8:00 AM EDT - 8 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 14, 2025, 7:45 AM EDT - 8 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

May 8, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 28, 2025, 7:00 AM EDT - 9 months ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:15 AM EDT - 10 months ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 11:17 AM EDT - 10 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 27, 2025, 7:30 AM EDT - 10 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 5:30 PM EDT - 10 months ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

Mar 24, 2025, 11:08 PM EDT - 10 months ago

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Mar 20, 2025, 7:15 AM EDT - 10 months ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:15 AM EST - 1 year ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 30, 2024, 4:30 PM EST - 1 year ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

Dec 12, 2024, 2:03 PM EST - 1 year ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 11:01 AM EST - 1 year ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 8, 2024, 1:14 PM EST - 1 year ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Oct 31, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 9:26 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jul 8, 2024, 2:00 AM EDT - 1 year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

CG

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Rox22
Rox22 Jan. 11 at 11:16 PM
$ADCT ruff!
0 · Reply
Spartrap
Spartrap Jan. 9 at 5:00 PM
$ADCT lol $73M what a dog 😂
1 · Reply
JohnTrack
JohnTrack Jan. 9 at 1:59 AM
$ADCT preliminary results https://www.rapidticker.com/news/adct-adc-therapeutics-provides-preliminary-fourth-e37d3d
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 8 at 9:32 PM
$ADCT
0 · Reply
JohnTrack
JohnTrack Jan. 2 at 11:21 PM
$ADCT watching for higher lows...
0 · Reply
JohnTrack
JohnTrack Jan. 2 at 9:34 PM
$ADCT quick blurb hit the feed!! https://www.rapidticker.com/news/adct-adc-therapeutics-announces-new-employee-9825ed
0 · Reply
fmalad
fmalad Dec. 30 at 2:22 AM
$ADCT it’s in an uptrend. Stop looking at a 5 day chart and stop day trading!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 10:15 PM
$ADCT RSI: 56.19, MACD: -0.1343 Vol: 0.37, MA20: 3.80, MA50: 4.02 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SamHot
SamHot Dec. 23 at 9:59 PM
$ADCT I couldn't resist
1 · Reply
Justrise07
Justrise07 Dec. 11 at 6:08 PM
$ADCT silent monster ! Shorts already started recovering! They read the new update & did dd , unstoppable next stop , welcome $CAPR
0 · Reply
josegodoy
josegodoy Dec. 11 at 12:44 AM
$ADCT
0 · Reply
jdkd4
jdkd4 Dec. 10 at 10:22 PM
$ADCT thx Jacksparo for another wonderful alert. Made a nice small profit. I set my own plan for this one and I’m executing it today. Follow the rules that I set!  sure I could lose out on more profit, but profit is profit is profit. I have learned that over and over again from my mentor, Jacksparo!!!!!!!
2 · Reply
Andysss
Andysss Dec. 10 at 8:26 PM
$ADCT told u. If u sold due to the data. Stop investing in biotech
1 · Reply
DARKP00L
DARKP00L Dec. 10 at 7:59 PM
$ADCT this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
Andysss
Andysss Dec. 10 at 3:02 PM
$ADCT some exited their short position. Will fly
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 10 at 1:06 PM
$VNDA $ADCT $CAPR $PBYI
0 · Reply
Andysss
Andysss Dec. 9 at 8:14 PM
$ADCT Market stating to understand the data.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 4:44 PM
$ADCT Share Price: $3.27 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $0.57 – $0.71 Target Zone: $0.92 – $1.12 Potential Upside: 51% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Arcides
Arcides Dec. 9 at 12:26 AM
$ADCT buyers are losing the battle.
0 · Reply
Adamchristlover
Adamchristlover Dec. 5 at 10:41 PM
$ADCT $CAPR $KALA $AQST $EKSO I support this post and approve it 100% as I am also part of Jack team and I have my brokerage statements for whoever needs it.
0 · Reply
jdkd4
jdkd4 Dec. 5 at 10:26 PM
$ADCT $CAPR $KALA $AQST $EKSO And many more tickers. I have made money, over $40,000 this week simply by following Jacksparo alerts!  I have very limited knowledge about investing, but I subscribe to his services and I can tell you for sure he over delivers most of the time! I am a very happy customer!!!! If you look at my post history you’ll see I have posted pictures of most of my trades to verify these. Thank you, Jack! You’re changing my life!
10 · Reply
alikp76
alikp76 Dec. 5 at 8:43 PM
$ADCT shit happens over and over again 🫥
0 · Reply